Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital

Ischemic Heart Disease Clinical Trial

Official title:

Study of Lipid Profile of Patients With Chronic Coronary Syndromes at Sohag University Hospital

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04977089
• Other study ID #: Soh-Med-21-07-01
• Status: Recruiting
• Start date: August 1, 2020
• Est. completion date: August 1, 2021

Study information

• Verified date: July 2021
• Source: Sohag University
• Contact: Islam M Farrag, resident
• Phone: 01092029333
• Email: islam010011[@]med.sohag.edu.eg
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic coronary syndrome (CCS) is a newly described classification devised by the European Society of Cardiology (ESC) 2019 to replace the term "Stable Coronary Artery Disease (CAD).

The main reason for effecting the change is the term is thought to better describe the disease process and encompass a wider spectrum of clinical, pharmacological, and pathophysiological entities.

Using this new term, the disease atherosclerosis manifests as CAD is categorized into Acute Coronary Syndrome (ACS) and CCS.

The main focus of introducing the concept of CCS is on the fact that CAD is a continuous phenomenon involving intravascular plaque aggregation and progression which has different evolutionary phases.

Dyslipidemia is recognized as a prominent risk factor for cardiovascular (CV) disease.

It is characterized by an elevation of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), or triglycerides (TG) and reduced serum high-density lipoprotein cholesterol (HDL-C) concentration .

Genetically determined and metabolically induced disturbances in lipid metabolism, as manifested in several types of dyslipidemia, have been shown to be causally related to the development of coronary artery disease (CAD).

A diversity of clinical and angiographic studies has been made to evaluate the linkage between plasma lipid-control therapy in the development of recurrent cardiovascular events.

Independent predictors of recurrent CVD events or death include age, smoking, hypertension (HTN), dyslipidemia, diabetes mellitus, chronic kidney disease, and the underutilization of medications recommended by current treatment guidelines.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 1, 2021
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• All patients have chronic coronary disease at Sohag University hospital who recieve drugs of anti hyperlipidemia .

Exclusion Criteria:

• Patients with first attack of acute coronary syndrome .

• Young patients <18 years .

• Old patients >65 years.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Dyslipidemias
• Heart Diseases
• Ischemic Heart Disease
• Myocardial Ischemia

Intervention

Diagnostic Test:
• lipid profile test .
Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )

Locations

Country	Name	City	State
Egypt	Sohag University Hospital	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Darroudi S, Saberi-Karimian M, Tayefi M, Arekhi S, Motamedzadeh Torghabeh A, Seyedzadeh Sani SMR, Moohebati M, Heidari-Bakavoli A, Ebrahimi M, Azarpajouh MR, Safarian M, A Ferns G, Esmaeili H, Parizadeh MR, Mokhber N, Mahdizadeh A, Mahmoudi AA, Sahebkar AH, Ghayour-Mobarhan M. Prevalence of combined and noncombined dyslipidemia in an Iranian population. J Clin Lab Anal. 2018 Oct;32(8):e22579. doi: 10.1002/jcla.22579. Epub 2018 Jun 21. — View Citation

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4242. — View Citation

Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 1):221-230. doi: 10.1016/j.jcmg.2017.01.029. Epub 2017 Jul 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dyslipidemia in chronic coronary syndrome	Pattern of dyslipidemia among patients with chronic coronary syndromes at sohag university hospital.	one year